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1. Introduction 
The oral route of drug administration is the most common and preferred route of drug delivery, however limited 
drug absorption resulting in poor bioavailability is paramount to the potential problems that can be encountered while 
delivering an active agent via oral route [1]. The drugs belonging to the biopharmaceutical classification system (BCS) 
class II and class IV dissolve slowly, poorly or irregularly, which results in the incomplete release of the drug from the 
dosage form. For these drugs, the dissolution process which is the rate-controlling step, determines the rate and degree of its 
absorption [2]. The challenge posed by such drugs can be addressed to a large extent by improving the solubility of the drug 
or the dissolution characteristics of the drug from dosage form.  
Raloxifene Hydrochloride (RLX HCl) is an oral selective estrogen receptor modulator (SERM); it is a 
benzothiophene that appears to have oestrogen agonist effects on bone and antagonist effects in uterine and breast tissue. It 
is used for the prevention and treatment of postmenopausal osteoporosis and to reduce the risk of invasive breast cancer in 
postmenopausal women who have osteoporosis or at high risk of invasive breast cancer [3]. RLX HCl is official in United 
States Pharmacopoeia. Chemically it is, Methanone, [6-hydroxy-2-(4-hydroxyphenyl) benzo[b]thien-3-yl][4-[2-(1-
piperidinyl)ethoxy] phenyl]-, hydrochloride. The molecular formula of RLX HCl is C28H27NO4S. HCl and its molecular 
weight is 510.04. RLX HCl is almost white to pale yellow powder.  It is very slightly soluble in water, in isopropyl alcohol, 
and in octanol; slightly soluble in alcohol; sparingly soluble in methyl alcohol; freely soluble in dimethyl sulfoxide; 
practically insoluble in ether and in ethyl acetate [4]. 
RLX HCl belongs to BCS class II as it possesses low water solubility and high membrane permeability [5]. It has 
an absolute bioavailability of approximately 2% in humans as it undergoes first-pass metabolism in the liver by 
glucuronidation and enterohepatic cycling. It has a half-life of approximately 27.7 hours. RLX HCl and its 
monoglucuronide conjugates are highly (95%) bound to plasma proteins [6]. The daily adult dose of the drug is 60 mg/day. 
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There is a need to improve the aqueous solubility or dissolution characteristics of RLX HCl to consequently increase its 
therapeutic effect. Hence in the present work RLX HCl tablets will be prepared using superdisintegrants, wetting agents, 
and surfactants etc. to enhance its dissolution rate and thus help improve bioavailability. 
 
2. Materials and methods 
2.1 Materials 
Raloxifene Hydrochloride was obtained as a gift sample from Sanika Chemicals. Micro Crystalline Cellulose 
(MCC), Ac-di-sol
®
 and Poly Vinyl Pyrollidone K30 (PVPK30) were obtained as gift samples from Signet Chemical 
Corporation Pvt. Ltd. All other chemicals and reagents used were either of Analytical or Pharmaceutical grade. 
2.2 Methodology 
2.2.1Preformulation study to evaluate drug-excipient compatibility [7-12] 
A preformulation study was carried out for 14 days for drug- excipient compatibility testing. The drug was mixed 
thoroughly with excipients in the ratio 1:1, 1:5 and 10:1 and kept in closed vials at 25°C and 40°C for 14 days, samples 
were also exposed to UV light for 24hrs (Table 1). The samples were observed visually for any physical changes. Samples 
were analyzed by spectrophotometry, DSC and FT-IR techniques.  
 
Table 1: Ratios of drug and various excipients used in preformulation studies 
Sr. no. Excipients evaluated Drug: excipient ratio 
1 Drug+ Polysorbate 80 1:1 
2 Drug+ Micro Crystalline Cellulose 1:5 
3 Drug+ Cross caramellose sodium (Ac-di-sol®) 1:5 
4 Drug+ Poly Vinyl Pyrollidone K30 1:5 
5 Drug+ Magnesium Stearate 10:1 
 
2.2.1.1 FT-IR Studies 
FT-IR spectroscopy was employed to ascertain the compatibility between RLX HCl and the selected excipients. 
The pure drug, drug-excipient combinations and formulations were subjected to FT-IR studies. The scanning range was 
400--4000 cm
-1
 and the resolution was 4 cm
-1
. The pure drug and the drug with excipients were scanned separately. FT-IR 
spectrum of drug-excipient mixtures was compared with that of the pure drug. 
2.2.1.2 DSC Studies 
Thermograms of pure drug and drug-excipient samples were recorded by differential scanning calorimeter (SII 
Nanotechnology, SEIKO, DSC 6220). Each sample was scanned in aluminum pan at a heating rate of 10 °C/min over the 
range of 50--300 °C with an empty aluminum pan used as reference. Samples were heated under nitrogen atmosphere (flow 
rate of N2, 50--60 ml/min). 
2.2.2 Analytical Method Development  
2.2.2.1 For Assay  
i. Preparation of RLX HCl standard stock solution (1000 μg/ml) in methanol 
A standard stock solution of RLX HCl was prepared by dissolving accurately weighed 25 mg of RLX HCl in 
methanol in a 25 ml volumetric flask and the volume was made up to 25 ml by using methanol to obtain a stock solution of 
1000 μg/ml. 
ii. Calibration curve of RLX HClin methanol 
From this stock solution, aliquots with suitable dilutions were made in order to get solutions with concentrations 
of2 μg/ml, 4 μg/ml, 6 μg/ml, 8 μg/ml, 10 μg/ml and 14 μg/ml. The absorbance was measured at 286 nm using UV visible 
spectrophotometer. The standard curve was obtained by plotting absorbance v/s concentration in μg/ml. The developed 
method was validated as per ICH guidelines [13, 14]. 
2.2.2.   For Dissolution  
i. Preparation of RLX HCl standard stock solution (1000 μg/ml) in 1% w/w Polysorbate 80 
A standard stock solution of RLX HCl was prepared by dissolving accurately weighed 25 mg of RLX HCl in small 
amount of methanol in a 25 ml volumetric flask and the volume was made up to 25 ml by using 1% w/w Polysorbate 80 to 
obtain a stock solution of 1000 μg/ml. 
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ii.  Calibration curve of RLX HCl in 1% w/w Polysorbate 80 
From this stock solution, aliquots with suitable dilutions were made in order to get solutions with concentrations of 
6μg/ml, 9μg/ml, 12μg/ml, 15μg/ml, 18μg/ml, 21 μg/ml, 24 μg/ml and 27μg/ml.  The absorbance was measured at 297 nm 
using UV visible spectrophotometer. The standard curve was obtained by plotting absorbance v/s concentration in μg /ml. 
The method was validated as per ICH guidelines [13, 14]. 
2.2.3 Preparation of RLX HCl tablets 
Nine batches of RLX HCl were formulated by varying concentrations of two of the excipients (DMSO and Ac-di-
sol
®
) to get a 2
3
factorial design (Table 2). The tablets were prepared by non-aqueous granulation technique. 
Table 2: Formulation of Raloxifene Hydrochloride tablets-Factorial design study 
Ingredients mg/tablet 
RLX 
HCl 20 
RLX 
HCl 21 
RLX 
HCl 22 
RLX 
HCl 23 
RLX 
HCl 24  
RLX 
HCl 25  
RLX  
HCl 26  
RLX 
HCl  27  
RLX 
HCl 28 
Raloxifene hydrochloride 60 60 60 60 60 60 60 60 60 
Ac-di-sol® 5 5 5 10 10 10 15 15 15 
DMSO 5 10 15 5 10 15 5 10 15 
MCC 222 222 222 222 222 222 222 222 222 
PVP K30 10 10 10 10 10 10 10 10 10 
Ac-di-sol® 5 5 5 5 5 5 5 5 5 
Mg Stearate  3 3 3 3 3 3 3 3 3 
Tablet weight 310 310 310 310 310 310 310 310 310 
2.2.4 Evaluation of tablets 
A. Pre-Compression Tests [15] 
The granules were evaluated for bulk density, tapped density, angle of repose, Hausner’s ratio, Carr’s 
compressibility index tests. 
B.  Post-Compression Tests [16-17] 
Compressed tablets were subjectedto thickness, hardness, friability, drug content, disintegration and dissolution 
tests. 
In-vitro dissolution studies 
In vitro dissolution studies for the prepared RLX HCl tablets were carried out using USP Type II dissolution 
apparatus at 37±1°C and 50 rpm using 900 ml 1% w/w Polysorbate 80 in water. Aliquots (5 ml) of the sample were 
withdrawn at 10, 20, 30, 45, 60, 90 and 120 minutes using a pipette and were replenished immediately with the same 
volume of fresh dissolution medium. Aliquots were filtered, suitably diluted and analyzed spectrophotometrically at 297 nm 
using a UV-3000 LABINDIA UV-Visible Spectrophotometer. 
2.2.5 Evaluation of data 
The dissolution data was fitted to various kinetic models to find the best fit model. Similarity factor and difference 
factor were determined in order to select the optimum formula for scale up and stability studies. 3D response plots were 
generated to find influence of various excipients on release pattern of drug from formulation. 
2. 2.6 Stability studies 
Preliminary trial batches and factorial batches for RLX HCl were formulated and in vitro dissolution studies for 
these batches were performed wherein the release pattern of each batch was found to be different. The batch exhibiting 
good dissolution profile with maximum drug release initially as well as at the end of 2 hours was selected for stability 
studies. Two stability batches batch nos. RLX HCl 29 and RLX HCl 30 were manufactured by scaling up the selected 
formula (Formula RLX HCl 27) and kept for stability studies according to the stability protocol made as per ICH 
guidelines. The effects of temperature, relative humidity and time on the physicochemical characteristics of the tablet were 
evaluated for assessing the stability of the prepared formulations. The different parameters that were studied are 
appearance, weight variation, hardness, thickness, disintegration time, assay and dissolution. Also the stability samples 
were evaluated for any degradation by DSC, FT-IR and XRD techniques. 
 
3. Results and discussion 
3.1. Preformulation study to evaluate drug- excipient compatibility 
3.1.1 Analysis by FT-IR  
C-O-C group represented by 1595.13 and C=O group represented by 1641.42 waves no. present in drug are also 
seen in mixtures of drug + excipients exposed to 40°C for two weeks indicating that there is no interaction between drug 
and excipients. (Fig. 1)  
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                 a) RLX HCl                                          b) Drug + Micro crystalline cellulose 
C-O-C stretching-1595.13                                      C-O-C stretching-1595.13 
C=O stretching-1641.42                                        C=O stretching-1641.42 
          
c) Drug + Ac-di-sol®                                                     d) Drug+ PVP K30 
C-O-C stretching-1597.06                                          C-O-C stretching-1500.62 
C=O stretching-1641.42                                                   C=O stretching-1649.14                       
            
e) Drug + Magnesium stearate 
C-O-C stretching-1595.13 
C=O stretching-1641.42 
 
Figure 1: FT-IR scans of a)RLX HCl, b)RLX HCl + Micro crystalline cellulose, c) RLX HCl + Ac-di-sol
®
, d) RLX 
HCl + PVP K30, e)RLX HCl + Magnesium stearate 
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3.1.2 Analysis by DSC 
In figure 2, scan a) shows DSC thermograph of pure drug (RLX HCl) singly and other scans [ b), c), d) and 
e)]show DSC thermographs of drug in combination with different excipients. Scans reveal that the melting point of RLX 
HCl is 269.9°C which is not altered to a great extent by the excipients used in the study. It may be concluded that all studied 
excipients are compatible with RLX HCl and can be used in formulation development.   
a) RLX HClb) Drug + Microcrystalline cellulose 
Melting Point: 269.9°C                                   Melting Point: 263.7°C 
 
c) Drug + Ac-di-sol®                                 d) Drug + PVP K30 
Melting Point: 250.9°C                                         Melting Point: 262.7°C 
 
e) Drug + Magnesium Stearate 
Melting Point: 259.2°C 
 
Figure 2:DSC scans of a)RLX HCl, b)RLX HCl + Micro crystalline cellulose, c) RLX HCl + Ac-di-sol
®
, d) RLX HCl 
+ PVP K30, e)RLX HCl + Magnesium stearate 
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3.1.3 Analysis by UV  
UV scans of RLX HCl + Polysorbate 80 (1:1), RLX HCl + MCC (1:5), RLX HCl + Ac-di-sol® (1:5) & RLX HCl 
+ PVP K30 (1:5) and RLX HCl + Magnesium stearate (10:1), initially and at room temperature, 40°C and UV/24 hours were 
found to elicit no change in wavelength maxima indicating the drug to be compatible with these excipients. 
3.2 Analytical method development 
3.2.1 For assay 
 
Figure 3: Spectra of Raloxifene Hydrochloride in methanol 
RLX HCl shows absorption maxima at 286 nm in methanol (Fig. 3) and corresponds to value mentioned in 
literature [18]. 
 
Figure 4: Calibration Curve of Raloxifene Hydrochloride in methanol 
Using the values obtained, graph was plotted (Fig. 4) and standard equation was derived. The coefficient of 
correlation was found to be 0.9972 indicating that the drug follows Beer Lambert’s law in the concentration range studied. 
The optical characteristics of the drug are recorded in Table 3.   
 Lambert’s law in the concentration range studied. The optical characteristics of the drug are recorded in Table 3.   
Table 3: Optical characteristics of Raloxifene hydrochloridein methanol 
Parameters Observed values 
λmax (nm) 286 nm 
Beer’s range (µg/ml) 2-14 µg/ml 
Correlation Coefficient (r²) 0.997 
Regression equation Y=0.0757x+0.0067 
Intercept (a) 0.0067 
Slope (b) 0.0757 
LOD 0.580 µg/ml 
LOQ 1.763 µg/ml 
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3.2.2 For dissolution 
 
Figure 5: Spectra of Raloxifene Hydrochloride in 1% Polysorbate 80 
RLX HCl shows absorption maxima at 297 nm in 1% Polysorbate 80 (Fig. 5) and corresponds to value mentioned 
in literature [11]. 
 
Using the values obtained, graph was plotted (Fig. 6) and standard equation was derived. The coefficient of 
correlation was found to be 0.9972 indicating that the drug follows Beer Lambert’s law in the concentration range studied. 
The optical characteristics of the drug are recorded in Table 4.   
 
Figure 6: Calibration Curve of Raloxifene Hydrochloride in 1% Polysorbate 80 
 
Table 4: Optical characteristics of Raloxifene hydrochloride in 1% Polysorbate 80 
Parameters Observed values 
λmax (nm) 297 nm 
Beer’s range (µg/ml) 6-27 µg/ml 
Correlation Coefficient (r²) 0.999 
Regression equation Y=0.0338x+0.0412 
Intercept (a) 0.0412 
Slope (b) 0.0338 
LOD 0.099 
LOQ 0.3 
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3.3. Assay for factorial batches 
Table 5: Results for assay of factorial batches 
Batch Percent drug content 
RLX HCl 20 95.08 
RLX HCl 21 98.68 
RLX HCl 22 108.36 
RLX HCl 23 107.06 
RLX HCl 24 98.68 
RLX HCl 25 99.97 
RLX HCl 26 97.68 
RLX HCl 27 106.16 
RLX HCl  28 105.86 
The drug content in all the batches were found to be within the prescribed limits of 90-110 % (Table 5) [4]. 
3.4 Dissolution profile for factorial batches 
Based on the results obtained for the factorial batches (Table 6) it was observed that these batches exhibited a 
better in vitro release profile as compared to the marketed preparation wherein batch no. RLX HCl 27 showed the highest 
amount of drug release at all the time intervals (Fig. 7). Therefore batch no. RLX HCl 27 was considered to be the best 
optimized formula exhibiting best dissolution profile of the drug.  
Table 6: Dissolution Profile for Trials Carried Out as Per Factorial Design 
Time 
(in mins) 
RLX 
HCl 20 
RLX 
HCl 21 
RLX 
HCl 22 
RLX 
HCl 23 
RLX 
HCl 24 
RLX 
HCl 25 
RLX 
HCl 26 
RLX 
HCl 27 
RLX 
HCl 28 
Marketed 
Batch 
10 29.28 31.36 30.09 36.17 32.74 31.94 35.78 39.08 26.11 28.9 
20 46.92 54.07 47.23 50.51 54.43 53.88 51.5 53.67 47.06 44.73 
30 62.8 61.56 63.51 61.81 67.6 66.05 70.4 68.33 60.19 57.55 
45 67.25 75.02 71.59 67.39 76.46 71.21 75.13 76.15 73.65 60.91 
60 70.71 81.62 74.78 72.06 79.37 76.49 78.39 79.46 76.75 65.59 
75 72.34 80.57 77.49 73.2 81.41 78.45 80.16 81.94 77.42 72.53 
90 73.78 79.26 77.76 74.79 82.55 81.37 82.15 83.93 80.09 69.44 
120 76.63 77.1 75.85 75.85 85.34 82.91 84.54 85.24 81.97 69.21 
 
 
Figure 7: Dissolution Profile for Trials Carried Out as Per Factorial Design 
3.5 Evaluation of data 
3.5.1 Difference factor (f1) and Similarity factor (f2) 
Of the nine batches, three batches had a far superior release profile and were compared with each other by 
determining the difference factor (f1) [19] and the similarity factor (f2)[19] to select the best formulation for stability studies 
20
30
40
50
60
70
80
90
0 30 60 90 120 150
P
er
ce
n
t 
R
el
ea
se
d
Time (in mins)
MARKETED
RLX HCl 20 
RLX HCl 21 
RLX HCl 22 
RLX HCl 23 
RLX HCl 24 
RLX HCl 25 
RLX HCl 26 
RLX HCl 27 
RLX HCl 28 
International Journal of Advances in Pharmaceutics 5 (6) 2016                                                                                 135 
 
 
(Table 7). According to the results obtained for the difference and the similarity factor it can be concluded that there exists a 
similarity between these three batches as the value obtained for the similarity factor value lies between 50-100 i.e., these 
three batches do not vary significantly with respect to dissolution profile. However there exists a minor statistically non-
significant difference between these three batches as the value obtained for the difference factor lies between 0-15. Batch 
nos. RLX HCl 24 and RLX HCL 27 contained minimum concentrations of Ac-di-sol
®
 and DMSO as compared to batch no. 
RLX HCl 28. Hence batch no. RLX HCl 28 was not selected for scale up and stability studies. Batch no. RLX HCl 27 
exhibited better drug release within initial 10 minutes as compared to batch no. RLX HCl 24. Hence the formulation was 
selected for scale up and stability studies. 
Table 7: Results for the Similarity factor and the Difference Factor for Batch Nos. RLX HCl 24, RLX HCl 26 and 
RLX HCl 27 
Batch no. Difference factor (f1) Similarity factor (f2) 
RLXHCl 24 and RLX HCl 26 0.3 % 82.85 % 
RLX HCl 24 and RLX HCl 27 1.391 % 79.75 % 
RLX HCl 26 and RLX HCl 27 1.717 % 83.4 % 
 
3.5.2Fitting of data to kinetic models 
Based on r
2
 values, the model that best fits drug release data was korsmeyer-peppas for batch nos. RLX HCL 21 to 
RLX HCl 28 (Table 8). In case of batch no. RLX HCl 20, the data fitted 1
st
 order model. 
Table 8: Fitting of data to kinetic models 
Formulation 
Code 
Zero order 
(r
2
) 
1
st
 order 
(r
2
) 
Higuchi 
(r
2
) 
Korsmeyer-
Peppas (r
2
) 
RLX HCl 20 0.683 0.892 0.815 0.871 
RLX HCl 21 0.583 0.529 0.734 0.833 
RLX HCl 22 0.629 0.564 0.775 0.859 
RLX HCl 23 0.716 0.644 0.846 0.910 
RLX HCl 24 0.685 0.592 0.820 0.873 
RLX HCl 25 0.709 0.605 0.837 0.878 
RLX HCl 26 0.687 0.613 0.818 0.884 
RLX HCl 27 0.726 0.654 0.853 0.916 
RLX HCl 28 0.701 0.598 0.834 0.880 
 
3.5.3 Response plots to determine influence of excipients on drug release 
 
Figure 8: 3D response plot for Amount of Drug Released in 1 hour (%) 
As the concentration of Ac-di-sol
®
 and DMSO increased from 5 to 15 mg, the amount of drug released in 1 hour 
increased (Fig. 8). Thus increase in concentration of both lead to improved dissolution characteristics. 
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Figure 9: 3D response plot for Dissolution Efficiency (D.E %) 
Dissolution Efficiency (%) was found to be highest at higher concentrations of Ac-di-sol
®
 and DMSO i.e. 10 
mg/tablet and 15mg/tablet respectively (Fig. 9). Thus, an optimum concentration of both provides highest dissolution 
profile. 
 
Figure 10: 3D response plot of Mean Dissolution Time 
As the concentration of Ac-di-sol
®
 and DMSO increased from 5 mg to 15 mg/tablet, an increase in the mean 
dissolution time was observed (Fig. 10). 
3.6 Results of stability studies 
The stability batches RLX HCl 29 and 30 were subjected to accelerated studies as per ICH guidelines. Three 
month data revealed that all physicochemical parameters remained within acceptable limits.  
 
Figure 11: Dissolution profile for stability batch no. RLX HCl 29 
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Initial dissolution profiles and 3 months 40°C/75%RH dissolution profiles of RLX HCl 29 and RLX HCl 30 were 
compared by finding the difference factor (f1) and the similarity factor (f2). Results indicated that both batches behaved 
similarly. Hence the formula is reproducible. 
Table 9: Results for the Similarity factor and the Difference Factor for batch nos. RLX HCl 29 and RLX HCl 30 
Batch No. 
Difference factor (f1) Similarity factor (f2) 
Initial 3 months 
40°C/75%RH 
Initial 3 months 40°C/75%RH 
RLX HCl 29 1.149 % 0.184 % 85.8 % 86.95 % 
RLX HCl 30 1.163 % 0.325 % 85.8 % 86.95 % 
 
3.6.1. Analysis of stability batch no. RLX HCl 29 by DSC  
DSC thermograms obtained for stability batch no. RLX HCl 29 showed no significant change in the endothermic 
peak initially and at the end of 3 months. Hence it can be concluded that the batch was found to be stable (Fig. 12). 
a) Initial                             b) After 3 months at 25°C/60%RH 
 
Melting Point: 269.9°C                                     Melting Point: 259.9°C 
Figure 12: DSC scan of a) RLX HCl 29 at 0 months, b) RLX HCl 29 after 3 months storage at 25°C/60%RH 
3.6.2. Analysis of stability batch no. RLX HCl 29 by FT-IR  
C-O-C group represented by 159.25 and C=O group represented by 1639.55 waves no. present in the initial sample 
are also seen in the samples exposed to 25°C/60%RH and 40°C/75%RH for three months indicating that the batch to be 
stable (Fig. 13). 
                           a) Initial                             b) After 3 months at 25°C/60%RH      c) After 3 months at 40°C/75%RH 
                  C-O-C stretching-1593.25                   C-O-C stretching-1593.25                       C-O-C stretching-1593.25                
                 C=O stretching-1639.55                        C=O stretching-1639.55                         C=O stretching-1639.55 
 
Figure 13: FT-IR scan of a) RLX HCl 29 at 0 months, b) RLX HCl 29 after 3 months storage at 25°C/60%RH, 
c)RLX HCl 29 after 3 months storage at 40°C/75%RH 
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3.6.3. Analysis of stability batch no. RLX HCl 29 by XRD 
XRD scans for stability batch no. RLX HCL 29 showed that the sample was crystalline in nature, as demonstrated 
by numerous distinct peaks observed at 2θ initially. The prominent peaks from initial sample at 2θ of were clearly seen at 
the same position in the samples exposed to 25°C/60%RH and 40°C/75%RH for 3 months. In addition, there is slight 
increase in crystallinity as it is evident by more number of diffractions at 40°C/75% RH (Fig. 14). This may have 
implications on long term dissolution profile of the formulation. 
                         a) Initial                          b) After 3 months at 25°C/60%RH      c) After 3 months at 40°C/75%RH  
 
Figure 14: XRD scan of a) RLX HCl 29 at 0 months, b) RLX HCl 29 after 3 month’s storage at 25°C/60%RH, c) 
RLX HCl 29 after 3 months storage at 40°C/75%RH 
 
4. Conclusion  
Analytical method development was done for both API and the formulation. Drug-excipient compatibility results 
exposed no incompatibility between drugs and various excipients. Following the preliminary trials for formulation of RLX 
HCl tablets, factorial batches were designed. The best optimized formula was finalized, scaled up into two batches and were 
put up on stability. Stability studies were carried out as per protocol. Results indicated that the stability batches complied 
with official as well as in house limits indicating that the drug is stable in the dosage form. The release profile indicates that 
around 85% of the drug is released at the end of 2 hours. Thus the developed formulation is a safe effective delivery system 
with increased aqueous solubility of RLX HCl thus improving in the dissolution characteristics and increasing the 
possibility of improved bioavailability. 
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